Chemotherapy Reduces Overall Survival in Children with Low-Grade Glioma

In this retrospective review of children with inoperable intracranial low-grade glioma, it was found that children treated with chemotherapy prior to radiation therapy had a lower 10yr overall survival rate of 85%, compared to 92% for children who… [Learn More…]

Multi-Session Gamma Knife Radiosurgery for Cancers of the Brain

Gamma Knife is a form of external stereostatic radiosurgery that uses 192 smaller beams of radiation to converge on a precise area of the body. With an accuracy of 0.5mm, Gamma Knife has minimal effects on surrounding healthy tissues and can be used… [Learn More…]

Nilotinib for Treatment of Newly Diagnosed Chronic Phase, Philadelphia Chromosome-Positive, CML

Imatinib was one of the first rationally designed drugs to specifically target the BCR-ABL fusion gene found in CML. Unfortunately, many patients eventually develop resistance to Imatinib. Nilotinib is a new drug designed to treat… [Learn More…]

Adjuvant Endocrine Therapy plus Zoledronic Acid in Premenopausal Women

Zoledronic acid is a drug used to treat bone metastasis. Addition of Zoledronic acid to either tamoxifen or anastrozole increased disease-free survival by 36% compared with either tamoxifen or anastrozole alone. At a median follow-up of just under… [Learn More…]

Vemurafenib (PLX4032) for Metastatic Melanoma

PLX4032 is a next generation oral BRAF inhibitor for the treatment of melanoma. Data from the BRIM 2 clinical trial of previously untreated melanoma patients showed that  53% of the patients experienced tumor shrinkage compared with only 5% for… [Learn More…]

Vismodegib for Basal Cell Carcinoma

Vismodegib is an inhibitor of the hedgehog signaling pathway, a pathway involved in regulating adult stem cells that is over-active in more than 90% of basal cell carcinomas. This phase II clinical trial resulted in an increased progression free… [Learn More…]

Amazing Results From ICT-107 Glioblastoma Clinical Trial

ICT-107 is a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma and is showing an 80.2% overall survival at 2yrs and 55% overall survival at 3yrs, with 38% of patients disease free at 3yrs…compared to a… [Learn More…]

DCVax: Slowing the Progression of Metastatic Prostate Cancer.

Prostate cancer patients whom experience rising PSA levels while on hormone treatment typically progress to metastatic disease on average in about 28-36 weeks. DCVax is a vaccine made from a patient’s own dendritic cells and loaded with a form of… [Learn More…]

JX-594: A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma

JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In this trial,… [Learn More…]

NICO Myriad: An Amazing New Surgical Tool!

This amazing new tool allows for minimally invasive brain tumor removal combined with extraction of live tumor samples in order to determine the most effective treatment protocol. I like this tool because it is highly innovative, has a modular… [Learn More…]